Evidence map›Paper›PMID 40331234›Full record

ArticleInternational journal of nanomedicine2025

A Super-Assembled Synergistically Nanoplatform AP@ZIF-8

Zhenzhen Luo, Dunhuang Wang, Lie Lin, Rui Zhou, Yuanyuan Su, Zongkai Zhang, Jing Hu, Yaqing Dai, Jingjing Wu, Xiaoyan Huang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhenzhen Luo *Shenzhen Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen, Guangdong, 518000, People's Republic of China.
Dunhuang Wang *Department of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, 361003, People's Republic of China.
Lie LinDepartment of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, 361003, People's Republic of China.
Rui ZhouDepartment of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, 361003, People's Republic of China.
Yuanyuan SuDepartment of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, 361003, People's Republic of China.
Zongkai ZhangDepartment of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, 361003, People's Republic of China.
Jing HuDepartment of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, 361003, People's Republic of China.
Yaqing DaiDepartment of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, 361003, People's Republic of China.
Jingjing WuDepartment of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, 361003, People's Republic of China.ORCID 0000-0002-7519-2647
Xiaoyan HuangDepartment of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, 361003, People's Republic of China.
Yufei ZhouDepartment of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, 361003, People's Republic of China.
Liuyun GongDepartment of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, 361003, People's Republic of China.ORCID 0000-0002-6795-8235

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Intensive cancer treatment with nanoplatform is widely exploited in the clinic, the emerging nanomedicine offers an unparalleled opportunity for encapsulating potential antitumor drugs in a nano-carrier. Apoptin (AP), a coding protein of VP3 gene, stem from the chicken anemia virus (CAV), can be activated in malignant cells selectively and prevents the dividing cancer cells from repairing their DNA lesions, thereby forcing them to undergo apoptosis. Herein, a three-step intelligent biodegradable drug delivery nanoplatform was designed. Methods: First, a hollow ZIF-8 was synthesized, embedded with platinum nanoparticle to form ZIF-8 Results: As expected, both in vitro and in vivo experiment demonstrated that AP@ZIF-8 Discussion: This work highlights a new strategy for liver cancer treatment and provides a reference for treating malignant tumors.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsAnimalsApoptosisCapsid ProteinsCell Line, TumorCell ProliferationDrug Delivery SystemsDrug LiberationHumansMetal NanoparticlesMiceMice, Inbred BALB CMice, NudeTumor MicroenvironmentAntineoplastic AgentsCapsid ProteinsVP3 protein, Chicken anemia virusapoptosisAP@ZIF-8PtPI3K-Akt signaling pathwaytumor-hypoxic microenvironment

Identifiers

PMID40331234
PMCPMC12051983

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.